136 related articles for article (PubMed ID: 24905321)
21. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
Pöyhiä R; Seppälä T; Olkkola KT; Kalso E
Br J Clin Pharmacol; 1992 Jun; 33(6):617-21. PubMed ID: 1389934
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
23. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
24. Central nervous system penetration of oxycodone after intravenous and epidural administration.
Kokki M; Välitalo P; Kuusisto M; Ranta VP; Raatikainen K; Hautajärvi H; Kokki H
Br J Anaesth; 2014 Jan; 112(1):133-40. PubMed ID: 24131664
[TBL] [Abstract][Full Text] [Related]
25. The pharmacokinetics of oxycodone after intravenous injection in adults.
Pöyhiä R; Olkkola KT; Seppälä T; Kalso E
Br J Clin Pharmacol; 1991 Oct; 32(4):516-8. PubMed ID: 1958450
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
28. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue.
Boström E; Jansson B; Hammarlund-Udenaes M; Simonsson US
Rapid Commun Mass Spectrom; 2004; 18(21):2565-76. PubMed ID: 15468158
[TBL] [Abstract][Full Text] [Related]
29. A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone.
Hulskotte LMG; Wilbrink-Pijffers I; Arbouw MEL; Benoist GE; Jansman FGA; van Berlo-van de Laar IRF
Biomed Chromatogr; 2024 Jul; 38(7):e5874. PubMed ID: 38587098
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
31. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain.
Kokubun H; Yoshimoto T; Hojo M; Fukumura K; Matoba M
J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):338-50. PubMed ID: 25359452
[TBL] [Abstract][Full Text] [Related]
33. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
34. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164
[TBL] [Abstract][Full Text] [Related]
35. Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
Lemberg KK; Kontinen VK; Siiskonen AO; Viljakka KM; Yli-Kauhaluoma JT; Korpi ER; Kalso EA
Anesthesiology; 2006 Oct; 105(4):801-12. PubMed ID: 17006080
[TBL] [Abstract][Full Text] [Related]
36. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
Kokki H; Rasanen I; Lasalmi M; Lehtola S; Ranta VP; Vanamo K; Ojanperä I
Clin Pharmacokinet; 2006; 45(7):745-54. PubMed ID: 16802855
[TBL] [Abstract][Full Text] [Related]
37. Dialyzability of Oxycodone and Its Metabolites in Chronic Noncancer Pain Patients with End-Stage Renal Disease.
Samolsky Dekel BG; Donati G; Vasarri A; Croci Chiocchini AL; Gori A; Cavallari G; Di Nino G; Mercolini L; Protti M; Mandrioli R; Melotti RM; La Manna G
Pain Pract; 2017 Jun; 17(5):604-615. PubMed ID: 27589376
[TBL] [Abstract][Full Text] [Related]
38. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
Fang WB; Lofwall MR; Walsh SL; Moody DE
J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
[TBL] [Abstract][Full Text] [Related]
39. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
40. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
